ALFA Finder| Revenue growth | 26.2% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin at 32% (37% excluding injectable facility and Stellon expenses). |
| Demand visibility | Strong, driven by increased business from existing customers and new acquisitions. |
| Management confidence | High; confident in outperforming industry growth and increasing wallet share. |
Growth
Revenue rose 26% YoY to ₹257.5 Cr; EBITDA grew 34% to ₹82.4 Cr with margins expanding 190 bps.
Outlook
Targeting 2-3 product launches annually; focus on injectable facility ramp-up and leveraging new approvals from ANVISA, PPB, and NDA.
Risks
Formulation revenue declined 23% YoY; regulatory compliance remains critical across diverse global manufacturing inspections.
Last quarter's promises, checked
Delivered
- Guided historical growth ~18% → delivered 26.2% (= BEAT)
- Guided API revenue growth → delivered 42% (= BEAT)
- Guided export recovery → delivered 46% surge (= BEAT)
Partly delivered
- Guided EBITDA margin 39-40% (adj.) → delivered 37% (adj.) (= PARTIAL)
Missed
- Guided formulation business recovery → delivered -23% YoY (= MISS)
Investor Presentation filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹599.30
- Market cap
- ₹12,539 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 44.4×Sector 43.8×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Other Announcement
Concord Biotech filed its quarterly shareholding pattern as of 5 November 2026. Promoters hold 39.54% of 20.92 crore shares.
Concord Biotech Bonus Issue
Concord Biotech allotted 10,46,16,204 bonus shares in a 1:1 ratio. Total equity shares rise to 20,92,32,408 after the bonus allotment.
Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY
Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹69.6 Cr · +10.3% YoY